Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 3,704 matching trials from the live ClinicalTrials.gov search.

Filters: Scottsdale, Arizona Clear all

Conditions: COVID-19
Interventions: PF-07321332, Ritonavir, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 78
States / cities: Pelham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 51 more

Conditions: Solid Tumor
Interventions: MFGR1877S; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 5
States / cities: Scottsdale, Arizona • Santa Monica, California • Aurora, Colorado + 2 more

Conditions: Parkinson Disease
Interventions: DBS Programming; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Respiratory Tract Viral Infections, Human Metapneumovirus (hMPV) Infection, Parainfluenza (PIV) Infection, Respiratory Syncytial Viral (RSV) Infection, Influenza Infection
Interventions: ALVR106, Placebo; Biological
Lead sponsor: AlloVir; Industry
Eligibility: 17 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 21
States / cities: Scottsdale, Arizona • Duarte, California • Gainesville, Florida + 16 more

Conditions: Relapsing Forms of Multiple Sclerosis
Interventions: BIIB091, DRF, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 23
States / cities: Scottsdale, Arizona • Berkeley, California • Orange, California + 20 more

Conditions: Astrocytoma, IDH-Mutant, Grade 4, Diffuse Glioma, Glioblastoma, IDH-Wildtype, Secondary Glioblastoma
Interventions: Ipilimumab, Magnetic Resonance Imaging, Nivolumab; Biological · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 413
States / cities: Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 288 more

Conditions: Hereditary Angioedema
Interventions: C1 esterase inhibitor [human] (C1INH-nf), Placebo (saline); Biological · Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 37
States / cities: Hoover, Alabama • Scottsdale, Arizona • Los Angeles, California + 34 more

Conditions: Ischemic Stroke, Systemic Embolism
Interventions: AtriClip LAA Exclusion System; Device
Lead sponsor: AtriCure, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6,573 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 102
States / cities: Huntsville, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 81 more

Conditions: Lateral Canthal Lines, LCL, Crow's Feet
Interventions: Vehicle, botulinum toxin, Type A; Biological
Lead sponsor: Eirion Therapeutics Inc.; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 19
States / cities: Scottsdale, Arizona • San Diego, California • Aventura, Florida + 16 more

Conditions: Pulmonary Embolism, Acute Pulmonary Embolism
Interventions: AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE; Device
Lead sponsor: Angiodynamics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 25
States / cities: Scottsdale, Arizona • Los Angeles, California • New Haven, Connecticut + 21 more

Conditions: Nasolabial Folds
Interventions: Sculptra Aesthetic 8ml, Sculptra Aesthetic 5ml; Device
Lead sponsor: Galderma R&D; Industry
Eligibility: 22 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 5
States / cities: Scottsdale, Arizona • Solana Beach, California • Bradenton, Florida + 2 more

Conditions: Hip Arthroscopy
Interventions: Hip Capsule Repair; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 50 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2040
U.S. locations: 3
States / cities: Scottsdale, Arizona • Westmont, Illinois • Rochester, Minnesota

Conditions: Multiple Myeloma
Interventions: CC-92328; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tampa, Florida + 2 more

Conditions: Advanced Solid Tumor Malignancies
Interventions: OMP-305B83; Drug
Lead sponsor: OncoMed Pharmaceuticals, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 4
States / cities: Scottsdale, Arizona • Aurora, Colorado • Ann Arbor, Michigan + 1 more

Conditions: Psychosis Associated With Alzheimer's Disease
Interventions: KarXT; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 148
States / cities: Homewood, Alabama • Chandler, Arizona • Gilbert, Arizona + 92 more

Conditions: Recurrent Hepatocellular Carcinoma, Refractory Liver Carcinoma, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8
Interventions: Cyclophosphamide, Cytokine-based Biologic Agent IRX-2, Nivolumab; Drug · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 3
States / cities: Scottsdale, Arizona • Duarte, California • Dallas, Texas

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: therapeutic nutritional supplementation, white wine, questionnaire administration; Other · Dietary Supplement
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 21 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 4
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 1 more

Conditions: Prostate Cancer
Interventions: Orteronel+Prednisone; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Myelodysplastic Syndrome, MDS, Trisomy 8
Interventions: rigosertib; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 5
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Rochester, Minnesota + 2 more

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: Ketogenic Diet; Other
Lead sponsor: Translational Drug Development; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 6
States / cities: Scottsdale, Arizona • Los Angeles, California • Danbury, Connecticut + 3 more

Conditions: Malocclusion
Interventions: Invisalign System; Device
Lead sponsor: Align Technology, Inc.; Industry
Eligibility: 11 Years to 19 Years
Enrollment: 164 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 8
States / cities: Scottsdale, Arizona • Rocklin, California • Roseville, California + 5 more

Conditions: Menstruation Disturbances, Premenstrual Syndrome
Interventions: levonorgestrel/ethinyl estradiol; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 744 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 69
States / cities: Scottsdale, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 61 more

Conditions: Primary Immune Thrombocytopenia (ITP)
Interventions: Efgartigimod IV, Placebo IV; Biological · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 18
States / cities: Phoenix, Arizona • Los Angeles, California • Oceanside, California + 15 more

Conditions: Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7, Stage II Renal Cell Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7
Interventions: Laboratory Biomarker Analysis, Placebo, Quality-of-Life Assessment, Sorafenib Tosylate, Sunitinib Malate; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1,943 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2021
U.S. locations: 966
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 601 more

Search by objective public record fields.

Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).

Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors

Advancing Pre-operative Targeting for Deep Brain Stimulation in the Globus Pallidus Internus

Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant

A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden

C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks

Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

ET-01 in Subjects With Lateral Canthal Lines, LCL-210

Evaluating the Safety and Efficacy of the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE for Treatment of Acute Pulmonary Embolism

Safety and Effectiveness of Sculptra Aesthetic for Correction of Nasolabial Folds.

CREST: Capsular Repair During Hip Arthroscopy

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer

White Wine or Nutritional Supplement in Improving Appetite in Patients With Cancer

Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer

Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome

Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer

Class II Correction Study Using the Invisalign System

Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery